LOGIN  |  REGISTER
Assertio
Assertio

Teladoc Health to Announce Third Quarter 2024 Financial Results

October 16, 2024 | Last Trade: US$6.83 0.07 -1.01

PURCHASE, NY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release third quarter 2024 results on Wednesday, October 30, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Conference Call Details

The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 781291. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=72270. A live audio webcast will also be available online at https://ir.teladoc.com/news-and-events/events-and-presentations/.

A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Teladoc Health

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.

Investors:
Michael Minchak
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-444-9612

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page